HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen Houston Selected Research

Monoclonal Antibodies

1/2018Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen Houston Research Topics

Disease

5Breast Neoplasms (Breast Cancer)
02/2016 - 07/2003
1Neoplasm Metastasis (Metastasis)
01/2018
1Melanoma (Melanoma, Malignant)
01/2018
1Neoplasms (Cancer)
01/2018
1Residual Neoplasm
01/2017
1Disease Progression
06/2012

Drug/Important Bio-Agent (IBA)

2Bevacizumab (Avastin)FDA Link
01/2018 - 06/2015
2Epirubicin (Ellence)FDA LinkGeneric
06/2015 - 02/2014
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/2015 - 02/2014
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2018
1Monoclonal AntibodiesIBA
01/2018
1Fluorouracil (Carac)FDA LinkGeneric
06/2015
1Docetaxel (Taxotere)FDA Link
06/2015
1Taxoids (Taxanes)IBA
02/2014
1GemcitabineFDA Link
02/2014
1Paclitaxel (Taxol)FDA LinkGeneric
02/2014
1AnthracyclinesIBA
02/2014
1AfatinibIBA
06/2012
1Trastuzumab (Herceptin)FDA Link
06/2012
1human ERBB2 proteinIBA
06/2012
1tipifarnib (R115777)IBA
07/2003
1TransferasesIBA
07/2003

Therapy/Procedure

4Neoadjuvant Therapy
01/2017 - 02/2014
3Drug Therapy (Chemotherapy)
01/2017 - 02/2014